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Abstract—Longitudinal observational databases have become
a recent interest in the post marketing drug surveillance com-
munity due to their ability of presenting a new perspective for
detecting negative side effects. Algorithms mining longitudinal
observation databases are not restricted by many of the limita-
tions associated with the more conventional methods that have
been developed for spontaneous reporting system databases. In
this paper we investigate the robustness of four recently developed
algorithms that mine longitudinal observational databases by
applying them to The Health Improvement Network (THIN) for
six drugs with well document known negative side effects. Our
results show that none of the existing algorithms was able to
consistently identify known adverse drug reactions above events
related to the cause of the drug and no algorithm was superior.
I. INTRODUCTION
Medical drugs are prescribed frequently throughout the
world but each time a patient takes a drug there is a risk of
the patient developing a side effect, referred to as an adverse
drug reaction (ADR). The purpose of a prescription drug is
to improve a patient’s medical state, but ironically, sometimes
ADRs can cause a patient’s medical state to deteriorate. To
prevent this occurring it is important to know all the ADRs
that can occur and to be able to identify patients that have a
high risk for developing a specific ADR. Obvious ADRs can
often be found during clinical trials but the main purpose of
a clinical trial is to determine the effectiveness of the drug
being tested and not to identify all the possible ADRs. Less
obvious ADRs, long term usage ADRs, ADRs resulting from
co-prescription of drugs or ADRs that occur in subgroups of
the population that are underrepresented in clinical trials (for
example children and pregnant females) can only be detected
by continuously monitoring patients who are prescribed the
drug after marketing, a process known as post marketing
surveillance.
The majority of the methods implemented for post mar-
keting surveillance use a database known as the Spontaneous
Reporting System (SRS) database containing voluntary reports
of suspected drug/s and adverse drug event pairs [1] [2] [3]
[4]. The SRS database is known to have duplicated, missing
and incorrect entries [5]. It is also common for SRS databases
to be prone to under-reporting as ADRs corresponding to
less serious medical events may not be reported or ADRs
that are very rare may never be suspected by anyone. As a
consequence of these issues, it may not be possible to identify
all ADRs by mining the SRS databases or identification may
only be possible after many thousands of patients have been
prescribed the drug and had the ADR. This is undesirable as
many patients may die before a rare but fatal ADR is identified.
A new type of medical database, known as the longitudinal
observational database (LOD), has recently gained interest
from the research community [6] for post marketing surveil-
lance as it does not rely on voluntary reports and offers a new
perspective for detecting ADRs. One example of a LOD is The
Health Improvement Network (THIN) database (www.epic-
uk.org) that contains medical and prescription records for all
registered patients at participating general practices in the UK.
General practitioners are required to enter all the medical
events they are made aware of, so serious but rare ADRs are
likely to be contained within the database.
There are currently four algorithms based on sequential
pattern mining techniques that have been developed to mine
LODs to detect ADRs but each algorithm has only been
applied to one type of LOD and there has been no research to
compare the four algorithms and identify conditions where one
algorithm is preferable. In this paper we applied the existing
algorithms to the THIN database for six drugs with generally
well known ADRs and compare the measure known as the
Mean Average Precision (MAP) [7] that indicates how well
each algorithm can rank known ADRs above medical events
that are unlikely to be ADRs from a collection of events. We
also calculated the precision of each algorithm on the top 10
and 50 ranked events for each drug.
The continuation of this paper is as follows. Section two
contains descriptions of the THIN database, the drugs investi-
gated and the four existing algorithms, including information
relating to the LODs each algorithm was previously applied to.
Details of the method use to compare the existing algorithms
can be found in section three. Section four contains the results
and is followed by a discussion of the implications of the
results in section five. The paper finishes with the conclusion
in section six.
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TABLE I: General information on the population of patients prescribed each drug that was investigated . Total is the number
of prescriptions of the drug in the database and includes repeat prescriptions, First is the number of first time prescriptions of
the drug and 13 months is the number of prescriptions where the drug was recorded as being prescribed for the first time in
13 months for a patient. The average age and gender ratio were calculated by considering all prescriptions of the drug.
Drug Total First 13 months Average Age (St Dev) Gender Ratio (F/M)
Ciprofloxacin 483 217 277 871 322 482 57.25(19.95) 1.28
Norfloxacin 30 043 15 160 17 390 59.23(19.74) 2.90
Doxepin 73 684 7607 8265 64.46(16.22) 2.65
Nifedipine 2 905 177 144 356 154 128 69.70(12.04) 1.09
Benzylpenicillin Sodium 1217 1003 1048 26.07(24.89) 1.10
Glibenclamide 418 473 15 222 16 445 67.83(11.38) 0.82
II. BACKGROUND
A. THIN Database
The THIN database consists of a collection of information
obtained from participating UK general practices including
information on patients such as their year of birth, gender
and family connections and the demographics of the area
they live in. The database also contains temporal information
detailing a patient’s prescription and medical event histories
since registration. For this comparison a database containing
records from 495 general practices was used. This subset of the
THIN database contained approximately four million patients,
over 358 million prescription entries and over 233 million
medical event entries.
Each medical event is recorded in the database by a ref-
erence code known as a Read code. The Read codes used
in the THIN database are an independent system designed
specifically for primary care but every ICD-9-CM (Interna-
tional Classification of Diseases, Ninth Edition, Clinical Mod-
ification) code (or analogues) have a corresponding Read code
[8]. The Read codes suffer from redundancy as different Read
codes can correspond to the same medical event, for example
there are 15 Read codes for the medical event ‘vomiting’
under a range of categories including ‘History/symptoms’,
‘Symptoms, signs and ill-defined conditions’, ‘Infections and
parasitic diseases’ and ‘Unspecified conditions’.
A known issue of the THIN database is that it is common
to have incorrect time stamps of medical events corresponding
to newly register patients. As patients can change general
practices at any age, when they register they may have a
history of events that a doctor needs to record. The term ‘reg-
istration event dropping’ is used when historic or previously
diagnosed events of newly registered patients are entered into
the database. For example, when a new patient first visits their
doctor they may inform the doctor of a previously diagnosed
chronic illness such as ‘diabetes’. This medical event will then
be input into the database with a date corresponding to the
visit, rather than the actual date the patient was diagnosed
with diabetes. As the dates recorded for the ‘registration event
drops’ are frequently incorrect, including them in a research
study will bias results. Research suggests that ’registration
event dropping’ is significantly reduced after a patient is
registered for a year. To prevent ’registration event dropping’
biasing the results in this study, the first 12 months of
medical history after registration are ignored for each patient
as justified in [9].
As patients can move to a different practice at any time (or
die), in this study we only include prescriptions into the study
where the corresponding patient is still active for a minimum
of 30 days after. This prevents the bias due to ‘under-reporting’
of ADRs that may occur if a patient no longer attends the
practice. The last date a patient is active is considered to be
the maximum date of any record for the patient or the patient’s
date of death.
B. Drugs Investigated
Six different drugs with variable attributes and prescrip-
tion indications (cause of the prescription) were chosen for
the investigation. The drug Nifedipine is a calcium channel
blocker that helps relax the smooth muscles in the heart and
blood vessels allowing blood to flow with greater ease and
is therefore used to treat prophylaxis of angina, hypertension
or Raynauds phenomenon. The penicillin Benzylpenicillin
Sodium and fluoroquinolones Ciprofloxacin and Norfloxacin
are three antibiotics used to treat bacterial infections. The other
two drugs investigated are Doxepin a tricyclic antidepressant
and Glibenclamide a sulfonylurea used to treat type 2 diabetes
mellitus.
The drugs Ciprofloxacin and Norfloxacin were chosen to in-
vestigate how good the data mining methods are when applied
to different drug population sizes (the collection of patients
prescribed the drug) as the majority of known ADRs are the
same for both drugs but the number of prescriptions recorded
in the database are 483 217 and 30 043 for Ciprofloxacin and
Norfloxacin respectively. The two drugs also have a similar
average age of the patients when prescribed the drug but have
different drug population gender distributions. Nifedipine was
previously chosen to investigate one of the existing algorithms,
so we also chose to use Nifedipine in this study to gain
some insight into how robust the existing algorithms are when
applied to different LODs.
Benzylpenicillin Sodium has the lowest number of prescrip-
tions of any of the drugs chosen for the study, with only 1217
prescriptions being recorded in the database. Benzylpenicillin
Sodium is also considered a fairly safe drug with only a
few known ADRs being listed. This will test how well the
algorithms do with small amounts of data and fewer ADRs to
detect. It also has the lowest average age that the patients are
prescribed the drug, 26 years, compared to the other drugs with
average ages ranging from 57 years to 70 years. Doxepin and
Glibenclamide were chosen for variety as they are prescribed
for different illnesses than the other drugs.
Table I presents the number of patients that are prescribed
each drug in the database and lists general statistics such as
the mean age and patient gender ratio (females/males) for each
drug and algorithm pair.
C. Existing Algorithms
1) Algorithm 1: Methods that are implemented on Spon-
taneous Reporting System (SRS) databases only have limited
information as the drug prescription rates and background in-
cident rates of medical events are both unknown. To overcome
these issues disproportionality methods are implemented as the
calculations are independent of the medical event and drug
prescription rates, due to these terms cancelling out during
division. The disproportionality methods make use of a con-
tingency table, see Table II. For example, a disproportionality
algorithm known as the Reporting Odds Ratio (ROR), first
contrasts how often the event of interest occurs with the
drug of interest compared to any other drug (w00w10 ) and then
compares this with the contrast of how often any other event
occurs with the drug of interest compared to any other drug
(w01w11 ), see Eq. 1.
ROR =
w00/w10
w01/w11
(1)
Previous work has investigated applying algorithms devel-
oped for SRS databases after transforming a LOD into a
SRS style database by inferring suspected drug and medical
events pairs that are ADRs [7]. Zorych et al. implemented
three different ways to map the LOD into an SRS database,
including a mapping called ’Modified-spontaneous reporting
system’ that incorporates the additional information on the
number of patients that do not have any suspected ADRs after
a drug and the background rate of medical events available in
LODs. They found that incorporating the addition information
did not improve results in the simulated and real databases
studied, consequently in this paper we chose to transform the
THIN database using their ’SRS mapping’ as this method is
more efficient. The values in the contingency table for drug X
and medical event Y using the ’SRS mapping’ are calculated
such that:
w00 is the number of distinct occurrences of event Y
within 30 days after the drug X is prescribed
w01 is the number of distinct occurrences of non Y
medical events that occur within 30 days after the
drug X is prescribed
w10 is the number of distinct occurrences of event Y
within 30 days after any drug other than X is
prescribed
w11 number of distinct occurrences of non Y events
within 30 days after any non X drug is prescribed.
TABLE II: Contingency table used in existing SRS methods.
Event j =Yes Event j =No
Drug i=Yes w00 w01
Drug i=No w10 w11
The SRS disproportionality algorithm implemented in this
paper is the ROR, where medical events are ranked in descend-
ing order of the left bound of the 90% confidence interval of
the ROR, Eq. 2, as previous work showed that the ROR05
was consistently better than the ROR [7].
ROR05 = exp(ln(
w00/w10
w01/w11
)−1.645×
√
1
w00
+
1
w01
+
1
w10
+
1
w11
)
(2)
2) Algorithm 2: Noren et al. developed, specifically for
LODs, a disproportionality based sequential pattern mining
algorithm that uses temporal information contained in LODs
to contrast the Observed to Expected ratio (OE ratio) of an
event and drug pair between two different time periods [10].
The database the OE ratio was developed for is the UK IMS
Disease Analyzer, a database containing UK general practice
records containing over two million patients and 120 million
prescriptions. The database contained 3445 drugs and 5753
medical events encoded by the ICD-10 [11]. When the UK
IMS Disease Analyzer database was mined by the OE ratio for
the drug Nifedipine it was found to have a precision10 = 0.7.
The OE ratio algorithm compares the number of patients
that have the first prescription of drug x (in thirteen months)
followed by event y within a set time t relative to the expected
number of patients if drug x and event y were independent.
Letting ntxy denote the number of patients that have drug x
for the first time and event y occurs within time period t, nt.y
denote the number of patients that are prescribed any drug for
the first time and have event y within time period t. ntx. denote
the number of patients that have drug x for the first time with
an active follow up in time period t and nt.. denote the number
of patients that have any drug for the first time with an active
follow up in time period t. The expected number of patients
that have drug x and then event y in a time period t is then,
Etxy = n
t
x.
nt.y
nt..
(3)
If for a given drug, the event occurs more than expected, the
ratio between the observed and expected will be greater than
one. By taking the log2 of the ratio, a positive value suggests
an interesting association between a drug and event. Modifying
the equation to prevent the problem of rare events or drugs
resulting in a small expectation that can cause volatility, a
statistical shrinkage method is applied.
IC = log2
ntxy + 1/2
Etxy + 1/2
(4)
The shrinkage adds a bias for the IC towards zero when an
event or drug is rare. The credibility intervals for the IC are
the logarithm of the solution to Eq. 5 with q = 0.025 and
q = 0.975.∫ µq
0
(Etxy + 1/2)
ntxy+1/2
Γ(ntxy + 1/2)
u(n
t
xy+1/2)−1e−(n
t
xy+1/2)du = q
(5)
The above can find possible drug and event associations of
interest for a given t, however, the authors suggest that general
temporal patterns can be found by comparing the IC of
two different time periods. The follow-up period of primary
interest is denoted by u and the control time period by v. This
removes event and drug relationships that just happen to occur
more in certain sub-populations. The difference between the
IC for both time periods is,
log2
nuxy
Euxy
− log2
nvxy
Evxy
(6)
re-arranging and adding a shrinkage term gives,
IC∆ = log2
nuxy + 1/2
Eu∗xy + 1/2
(7)
where
Eu∗xy =
nvxy
Evxy
.Euxy (8)
In this paper we calculate the IC∆ as described above by
contrasting the 30 day period after the drug prescription with
a time period of 27 to 21 months prior to prescription. The OE
ratio ranks medical events in descending order of the IC∆, but
removes some noise by filtering medical events with a positive
IC a month prior to the prescription or with a positive IC on
the day of prescription. As the THIN database does not contain
information on the time during the day that a prescription is
issued or a medical event is recorded, it is possible that medical
events occurring on the same day as the prescription may be
ADRs, so we investigate two different implementations of the
OE ratio, the OE ratio 1 filters medical events with an IC value
a month prior to the prescription greater than the IC value in
the month after (not including the day of prescription) and OE
ratio 2 filters every medical event with an IC value a month
prior to the prescription or on the day of prescription that is
greater than the IC value a month after.
3) Algorithm 3: Mining Unexpected Temporary Associa-
tion Rules given the Antecedent (MUTARA) [12] is a se-
quential pattern mining algorithm that finds medical events
that occur more than expected within a user defined time
period after a drug is first prescribed. MUTARA implements
a measure of interestingness frequently used in sequential
pattern mining known as Leverage. In the context of the
medical databases the Leverage gives an indication of how
temporally dependent a medical event is on the the presence
of a drug, as it is the number of patients that have the medical
event after the first time they are prescribed the drug of
interest minus the expected number of patients who would
have the medical event if the presence of the medical event
was independent of the presence of the drug.
MUTARA was developed to be originally implemented on
the Queensland Linked Data Set (QLDS) comprising of the
Commonwealth Medicare Benefits Scheme (MBS), Pharma-
ceutical Benefits Scheme (PBS) and Queensland Hospital mor-
bidity data. The database contained 2020 different diagnoses
(medical events) and 758 distinct drug codes. The database
contains limited information on a patient’s medical history,
as it only contains information while a patient is in hospital.
When MUTARA was applied to the QLDS to detect ADR for
older females prescribed alendronate the precision of the top
ten events (precision10) was 0.1.
It is common for patients to have medical events repeated
in their sequence and if a patient has a disease shortly before a
prescription and then again within T days of the prescription it
is unlikely that the disease is an ADR. As a consequence, the
authors of MUTARA decided to filter ‘predictable’ medical
events by removing any medical events that occurred T days
after the drug prescription and also occurred in a user defined
time period prior to the drug prescription.
If we let P (X
T
↪→ Y ) denote the probability of having event
Y ‘unpredictably’ within T days of drug X , then if event Y
occurs independent of drug X , P (X
T
↪→ Y ) = P (X).P ( T↪→
Y ). A large value for P (X
T
↪→ Y ) − P (X).P ( T↪→ Y ) would
then suggest a dependency of Y on drug X , indicating Y as
a possible ADR.
The above measure can be estimated by,
Unexlev = Supp(X
T
↪→ Y )− Supp(X).Supp(
T
↪→ Y )
Population
(9)
Where,
• Supp(X
T
↪→ Y ) - the number of patients in the database
that have the medical event Y within T days of the first
time being prescribed drug X and do not have medical
event Y in a user defined time period prior to X .
• Supp(X) - the number of patients in the database that
are prescribed the drug of interest.
• Supp(
T
↪→ Y ) - the number of patients who have never
been prescribed drug X and have medical event Y in a
randomly chosen time period of T days plus Supp(X
T
↪→
Y ).
• Population - the total number of patients
MUTARA calculates the Unexlev for each medical event
input by the user (in this paper we input any medical event that
occurs within 30 days of the first time the drug is prescribed
for at least one patient) and returns a ranked list in descending
order of the Unexlev.
In this paper we use T=30 and chose to investigate two
different time periods prior to the prescription that determine if
a medical event is ‘predictable’, 180 days and 60 days directly
prior to the day the drug is first prescribed (MUTARA180 and
MUTARA60 respectively).
4) Algorithm 4: Highlighting UTARs Negating TARs
(HUNT) is a modified version of MUTARA [13], originally
developed and implemented on the QLDS with previous
results of a precision10 = 0.3 when applied to detect ADR for
older females prescribed alendronate and a precision10 = 0.1
when applied for older males. MUTARA was found to have
problems distinguishing between ADRs and therapeutic fail-
ures, as therapeutic failure medical events frequently occur
after the drug is prescribed and have a high Unexlev value.
Both therapeutic failures and ADRs have a high Unexlev, but
unlike ADRs, therapeutic failure medical events should also
occur prior to the drug prescription for some patients. The
‘predictable’ filter should impact on therapeutic failure events
but not ADRs, so the rank of therapeutic failure events can be
reduced by comparing the Unexlev with the standard Leverage
that calculates the temporal dependency of a medical event on
a drug but does not filter ‘predictable’ events, see Eq. 10.
Leverage = Supp(X
T→ Y )− Supp(X).Supp(
T→ Y )
Population
(10)
Where,
• Supp(X T→ Y ) - the number of patients in the database
that have the medical event Y within T days of the first
time being prescribed drug X .
• Supp(X) - the number of patients in the database that
are prescribed the drug of interest.
• Supp( T→ Y ) - the number of patients who have never
been prescribed drug X and have medical event Y in a
randomly chosen time period of T days plus Supp(X T→
Y ).
• Population - the total number of patients
HUNT calculates both the Unexlev and Leverage values,
assigns each medical event two ranks (RANKUnexlev and
RANKLeverage) based on the Unexlev and Leverage values
respectively in descending order and finally returns the list of
medical events in decreasing order of the rank ratio (RR),
RR =
RANKLeverage
RANKUnexlev
(11)
In this paper HUNT is implemented with the same param-
eters as described for MUTARA.
III. COMPARISON METHOD
Each data mining algorithm is applied to the THIN database
and a ranked list of medical events is returned. The events
are ranked in descending order of the association between the
drug of interest and event, so events the algorithm has deemed
more likely to be ADRs are ranked higher, an example of
this can be seen in Table III. The algorithm is then analysed
by investigating how well it has ranked each of the known
ADRs that have occurred in the returned ranked list. The
known ADRs are those that are listed in the British National
Formulary (BNF) [14] for the specific drug, or medical events
of type ‘adverse reaction to drug x’ or containing information
about the continuation of the drug prescription.
Given a ranked set of events, we calculate the Truth measure
y(i) for the ith ranked event, by letting y(i) = 1 if the event is
TABLE III: An example of the medical event list associated
to a specific drug and ordered by one of the algorithms.
Event Rank Score ADR y(i)
Event 1 2.34 No y(1) = 0
Event 5 2.12 Yes y(2) = 1 precision2 = 1/2
Event 4 1.75 Yes y(3) = 1 precision3 = 2/3
Event 2 1.74 No y(4) = 0
Event 3 0.68 No y(5) = 0
a known ADR and y(i) = 0 otherwise, as shown in Table III.
Table III shows an example of a returned list containing five
events ranked by an algorithm and the corresponding y values.
Using the y values we can then use the measures described
below to compare the different algorithms.
A. Precision K
The precisionk of each algorithm is defined as the fraction
of known ADRs that occur in the top k events of the list
returned by each algorithm for a specific drug, see Eq. (12).
Precisionk =
∑k
i=1 y(i)
k
(12)
In this study two k values are investigated, k = 10 and k = 50.
B. Mean Average Precision
The mean average precision (MAP) is a measure that
can be used to determine how well an algorithm generally
ranks the medical events associated to a drug. This measure
has previously been applied to compare SRS data mining
algorithms adapted to be implemented on a LOD [7] and was
also used in the Observational Medical Outcomes Partnership
(OMOP) Cup, a competition where contestants were required
to detect ADRs in a generated LOD [15].
The MAP is calculated by finding the average precisionk
for each k corresponding to a known ADR,
MAP =
∑
K:y(K)=1
precisionK∑
i y(i)
(13)
Using Table III as an example, as there are two known
ADRs returned (
∑
i y(i) = 2) and the known ADRs in the
table are ranked second and third we have {K : y(K) = 1} =
{2, 3}, so the MAP score is,
MAP =
precision2 + precision3
2
=
1/2 + 2/3
2
=
7
12
(14)
It was also possible to investigate how well each algorithm
ranks the known ADRs depending on how common they are.
As the BNF states the risk of each known ADR by separately
listing frequently, less frequently and rarely occurring known
ADRs we also calculated the MAP score of each algorithm
when only considering rarely occurring known ADRs (as
unknown ADRs are likely to be rare). We calculate the MAP
scores for three different situations; considering all known
ADRs, only considering rare known ADRs and lastly, only
considering Read codes mentioning ‘adverse reaction to drug
x’ or a change in prescription.
TABLE IV: Precision10 for the different drug and algorithm combinations.
Drug precision10OE Ratio 1 OE Ratio 2 MUTARA60 MUTARA180 HUNT60 HUNT180 ROR05
Norfloxacin 0 0 0.1 0.1 0 0 0
Benzylpenicillin Sodium 0 0 0 0 0.1 0 0
Nifedipine 0.3 0.4 0 0 0.4 0.5 0
Doxepin 0.1 0.1 0.2 0.4 0.2 0.3 0
Glibenclamide 0 0 0 0 0.1 0 0
Ciprofloxacin 0 0.1 0.2 0.2 0.2 0.1 0
Mean (3dp) 0.067 0.100 0.083 0.117 0.167 0.150 0
TABLE V: Precision50 for the different drug and algorithm combinations.
Drug precision50OE Ratio 1 OE Ratio 2 MUTARA60 MUTARA180 HUNT60 HUNT180 ROR05
Norfloxacin 0.02 0.04 0.1 0.1 0.08 0 0
Benzylpenicillin Sodium 0.08 0.06 0.08 0.08 0.04 0.02 0.04
Nifedipine 0.2 0.26 0.12 0.16 0.2 0.22 0
Doxepin 0.1 0.l 0.12 0.14 0.18 0.22 0
Glibenclamide 0.02 0.02 0.02 0 0.04 0.02 0.06
Ciprofloxacin 0.02 0.02 0.12 0.14 0.10 0.08 0.02
Mean (3dp) 0.073 0.083 0.093 0.103 0.107 0.093 0.02
IV. RESULTS
A. Precisionk
It can be seen in Table IV that overall HUNT60 had the
highest precision10 and the worse performing is the ROR05. At
a 1% significance level there was not enough evidence to show
any of the algorithms had a significantly greater precision10
than any other algorithm (one sided paired Mann-Witney U-
test with multiple testing correction, p=0.01).
HUNT60 also had the greatest average precision50, see Table
V. Similarly to the precision10, none of the algorithms had
a significantly greater precision50 (one sided paired Mann-
Whitney U-test with multiple testing correction, p=0.01).
B. Mean Average Precision
Fig. 1a displays the general MAP scores using all the known
ADEs listed on the BNF website for the different algorithms
applied to the different drugs. The results can be split into
three different drug groups. The first group of drugs, Doxepin,
Norfloxacin and Ciprofloxacin all show a similar trend with
MUTARA (MUTARA60 and MUTARA180) performing the
best. The next group, Glibenclamide and Benzylpenicillin
Sodium, show MUTARA outperforming the OE ratio but with
HUNT60 being the best performing algorithm. Lastly, the
remaining group consisting of just one drug, Nifedipine, shows
a unique trend with MUTARA performing relatively poorly
and the OE ratio algorithm producing the best result. The MAP
scores for all the drugs apart from Glibenclamide range from
0.04 − 0.18, with the MAP scores of Glibenclamide ranging
from 0.01− 0.04.
Fig. 1b shows the MAP scores for the algorithms when
only considering rare known ADEs. The MAP scores for all
the algorithms range between 0 − 0.03. The group of drugs
Doxepin, Glibenclamide and Nifedipine have MAP scores
less than 0.005 whereas Norfloxacin, Ciprofloxacin and Ben-
zylpenicillin Sodium have MAP scores between 0.01− 0.03.
There was no algorithm that had a consistently greater MAP
score over all the drugs, but the ROR05 performed the worse
for five out of the six drugs investigated.
V. DISCUSSION
The results show that all the existing algorithms have
difficulty detecting rare known ADRs as, for each algorithm,
the MAP score when only considering rare ADRs was much
lower than the corresponding MAP score when including all
the known ADRs. It can also be observed that the MAP scores
for Glibenclamide a drug from the class of medications called
sulfonylureas that are known for rarely causing ADRs was
lower than for all the other drugs. The ability of the existing
algorithms in detecting rare ADRs needs to be improved for
them to be able to offer new information that cannot be found
by mining SRS databases. Another limitation with the existing
algorithms is the variety of parameters that may need to change
depending on the drug being studied and an improvement for
each algorithm would be to develop a way to learn the suitable
parameters dependent of the type of drug being investigated.
Fig 1a shows two important results, firstly that the algo-
rithms are not robust, as their MAP scores varied across the
different drugs and secondly that no algorithm was consistently
better than the rest. As a consequence, at current, it would be
better to apply all the algorithms when mining LODs to detect
ADRs and further investigate possible ADRs that are highly
ranked by the majority of the algorithms.
Both MUTARA and HUNT estimate the background rate
of a medical event by calculating how often the medical event
occurs during some random time period for each patient that
was not prescribed the drug. As the time period chosen for
each non drug patient will change every time the algorithm
is implemented, the results of MUTARA and HUNT will
be different. In this study we did not investigate how much
the MAP scores vary because of this and this is something
that needs further investigation. MUTARA and HUNT were
developed to be applied to a patient population of a specified
age group and gender but in this study we applied them to
(a) The general MAP scores for the different algorithms applied to the range of drugs.
(b) The MAP scores corresponding to the rare known ADEs for the different algorithms applied to the range of drugs.
(c) The MAP scores rating the algorithms ability to rank Read codes specifying ‘adverse drug reaction to x’ or indicating a change in
prescription applied to the range of drugs.
Fig. 1: Bar charts of the algorithm MAP scores.
any age and gender as partitioning the drug population often
causes an increase in the time it takes before rare ADRs are
detected. By applying MUTARA and HUNT to the whole drug
population we increased the effects of confounding as the non
drug population are likely to have different age and gender
distributions. Interestingly, MUTARA and HUNT performed
better for Nifedipine than Norfloxacin and Ciprofloxacin even
though there was less gender bias in the population of patients
prescribed Nifedipine, this suggests that MUTARA and HUNT
may still be suitable even when the drug patient population are
a wide mix of different ages and genders. A final observation
of the HUNT and MUTARA algorithms is the effect that the
length of time prior to prescription used to filter ‘predictable’
medical events has on the ability of HUNT and MUTARA
to identify ADRs that have a high background rate. For
the drugs Doxepin, Norfloxacin, Ciprofloxacin and Nifedipine
filtering medical events that occurred 180 days prior to the
prescription improved the algorithms ability to detect ADRs
but this was not the case for Benzylpenicillin sodium and
Glibenclamide, where HUNT60 perform much better than
HUNT180. A likely reason for this is that many of the known
ADRs for Benzylpenicillin sodium and Glibenclamide are
generally common medical events and the longer the time
period investigated prior to the prescription the more likely
the common ADRs are to be filtered, this suggests that the
algorithms should be implemented with multiple time period
used for filtering as we do not know if the medical events that
are unknown ADRs have a high prevalence or not.
The case series approach of the OE ratio, comparing the
same population at two different periods of time, reduces the
confounding of age, gender and medical state but still has
issues as a patient’s medical state may have drastically changed
over the two years and medical events that are related to the
cause of the prescription are only likely to occur after the drug
and not prior to the prescription. If event relationships could
be learned, the filters implemented by the OE ratio could not
only filter medical events that occur more than expected on the
day of prescription or a month prior to prescription but could
also filter temporally related medical events. We also stated
that we wanted to investigate the possible issue of filtering
medical events that occur more than expected on the day of
prescription, as ADRs may be reported the same day and be
incorrectly filtered. By looking at Fig 1c we can see that the
OE ratio 1 generally performed better than the OE ratio 2
for medical events corresponding to ‘had adverse reaction’ or
‘patient’s prescription changed’ suggesting filtering medical
events that occur more than expected on the day of prescription
may prevent detection of some ADRs.
The algorithms appear to be robust over different LODs, as
the precision10 results of the MUTARA180/HUNT180 applied
to THIN averaged 0.117 and 0.150 respectively and were
previously found to be 0.1 and 0.3/0.1 respectively. The OE
ratio applied to Nifedipine had a lower precision10= 0.4
when applied to THIN, however the authors of the OE ratio
stated that when they implemented the algorithm they removed
administrative events resulting in a precision10 = 0.7 for
Nifedipine, and although we ignored Read codes under the
administration category, other Read codes that were included
may be considered administration events, ignoring any event
that could be considered an administration event resulted in a
more comparable precision10 = 0.6 when the OE ratio 2 was
applied to THIN.
VI. CONCLUSION
We applied four existing algorithms developed to detect
ADRs by mining LODs by implementing them on the THIN
database. Our results show that no algorithm outcompeted
the others, the existing methods had difficulty detecting rare
ADRs and none of the algorithms was robust over all the drugs
investigated. Future work needs to investigate ways to learn
suitable parameters for each algorithm depending on the drug
being investigated and ways to filter illness progression and
therapeutic failure events.
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